Business Context and Reporting Period
This Form 8-K is filed by Silexion Therapeutics Corp, a Cayman Islands-based emerging growth company, on August 13, 2026. The report addresses Item 8.01 (Other Events) regarding the implementation of a 1-for-10 reverse share split approved by shareholders in April and May 2026. The split became effective on May 29, 2026, with trading on the Nasdaq Capital Market commencing on a post-split basis.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it serves as a notice that the Company has retroactively adjusted share counts, per-share data, and option/warrant information in its audited financial statements for the year ended December 31, 2025, and its unaudited interim statements for the quarter ended March 31, 2026. These adjusted statements are attached as Exhibit 99.1 and 99.2.
Material Changes
- Reverse Share Split: A 1-for-10 reverse split was effected on May 28, 2026, reducing the number of outstanding ordinary shares and increasing the share price proportionally.
- Financial Statement Adjustments: Historical financial data for the periods ending December 31, 2025, and March 31, 2026, has been restated to reflect the new share structure.
- Warrant Exercise Price: The filing lists warrants (SLXNW) with an exercise price of $15,525.00 per share, reflecting the post-split adjustment.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the reverse split mechanics. The primary focus is the administrative update to financial reporting to align with the new capital structure.
Investor Verification Checklist
- Verify the adjusted share count and per-share metrics in the attached Exhibit 99.1 (Audited statements for 2025) and Exhibit 99.2 (Unaudited statements for Q1 2026).
- Confirm the updated exercise price of outstanding warrants ($15,525.00) and the impact on dilution calculations.
- Review the Company's cash position in the restated financial statements to assess runway post-split.
- Check Nasdaq Capital Market compliance status following the reverse split implementation.